

**EDWARDS LIFESCIENCES CORPORATION**  
**Unaudited Consolidated Statements of Operations**

Three Months Ended  
**March 31,**  
**2007      2006**

(in millions, except per share data)

Net sales	\$264.1	\$256.7
Cost of goods sold	93.2	93.1
Gross profit	170.9	163.6
Selling, general and administrative expenses	98.6	92.2
Research and development expenses	28.8	27.2
Special gains, net	-	(23.8)
Interest expense, net	0.2	0.9
Other expenses (income), net	(1.3)	0.7
Income before provision for income taxes	44.6	66.4
Provision for income taxes	11.4	20.5
Net income	\$33.2	\$45.9
<b>Earnings per share:</b>		
Basic earnings per share	\$0.57	\$0.77
Diluted earnings per share	\$0.54	\$0.73
<b>Weighted average common shares outstanding:</b>		
Basic	57.9	59.3
Diluted	63.5	64.6

**Operating Statistics**

As a percentage of net sales:

Gross profit	64.7%	63.7%
Selling, general and administrative expenses	37.3%	35.9%
Research and development expenses	10.9%	10.6%
Income before provision for income taxes	16.9%	25.9%
Net income	12.6%	17.9%
Effective tax rate	25.6%	30.9%

**Computation of Diluted Earnings per Share**

Net income	\$33.2	\$45.9
Adjustment for interest expense included in net income	1.0	1.0
Adjusted net income	\$34.2	\$46.9
Weighted average common shares outstanding used to calculate diluted earnings per share excluding contingent convertible debt	60.8	61.9
Weighted average common shares outstanding for the contingent convertible debt	2.7	2.7
Weighted average common shares outstanding used to calculate diluted earnings per share including the contingent convertible debt	63.5	64.6
Diluted earnings per share including the contingent convertible debt	\$0.54	\$0.73

Note: Numbers may not foot due to rounding

**EDWARDS LIFESCIENCES CORPORATION****Unaudited Balance Sheets**

(in millions)

	<u>March 31, 2007</u>	<u>December 31, 2006</u>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$180.2	\$182.8
Accounts and other receivables, net	129.3	127.1
Inventories, net	141.5	142.1
Deferred income taxes	26.8	21.8
Prepaid expenses and other current assets	64.3	57.8
	<hr/>	<hr/>
Total current assets	542.1	531.6
Property, plant and equipment, net	216.7	213.0
Goodwill	337.7	337.7
Other intangible assets, net	108.9	116.1
Investments in unconsolidated affiliates	22.2	20.2
Deferred income taxes	6.3	14.5
Other assets	15.3	13.7
	<hr/>	<hr/>
Total assets	<u><u>\$1,249.2</u></u>	<u><u>\$1,246.8</u></u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Accounts payable and accrued liabilities	\$179.4	\$226.2
Long-term debt	224.5	235.9
Other long-term liabilities	60.3	35.3
<b>Stockholders' equity</b>		
Common stock	67.6	67.0
Additional contributed capital	626.6	603.7
Retained earnings (1)	468.8	433.9
Accumulated other comprehensive loss	(13.8)	(15.8)
Common stock in treasury, at cost	(364.2)	(339.4)
	<hr/>	<hr/>
Total stockholders' equity	785.0	749.4
	<hr/>	<hr/>
Total liabilities and stockholders' equity	<u><u>\$1,249.2</u></u>	<u><u>\$1,246.8</u></u>

(1) Effective January 1, 2007, the Company adopted Financial Accounting Standard Board ("FASB") Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109" ("FIN 48"). The adoption of FIN 48 increased the beginning balance of retained earnings by \$1.7 million.

## EDWARDS LIFESCIENCES CORPORATION

### Non-GAAP Financial Information

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses non-GAAP financial measures that exclude certain items, such as in-process research and development expenses, special charges and gains, results of discontinued products, and fluctuations in exchange rates. Management does not consider the excluded items part of day-to-day business or reflective of the core operational activities of the Company as they result from transactions outside the ordinary course of business.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. Certain guidance is provided only on a non-GAAP basis that excludes special items and foreign exchange fluctuations due to the inherent difficulty in forecasting such items. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the Company's core operating results and trends for the periods presented.

Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, nor superior to, the corresponding measures calculated in accordance with GAAP.

#### **The items described below are excluded from the GAAP financial results in the reconciliations that follow:**

**Special gains, net** - The Company incurred certain special charges and gains in 2006 related to the following:

- 1) *Realignment expenses: \$2.1 million charge for primarily severance expenses in the first quarter of 2006 resulting from the planned closing of a manufacturing facility;*
- 2) *Gain on sale of products: \$5.7 million gain from cash received in the first quarter of 2006 as the final earn-out payment in the prior year's sale of the Japan Perfusion product line to Terumo;*
- 3) *Gain on patent settlement: \$20.2 million gain from a patent settlement with Medtronic in the first quarter 2006.*

Given the magnitude and unusual nature of these special charges and gains relative to the operating results for the periods presented, these items have been excluded from non-GAAP net income.

**Results of Discontinued Products** – The Company has exited certain products during the periods presented. As discontinued products do not have a continuing contribution to operations, management believes that excluding such items from the Company's sales growth provides investors with a means of evaluating the Company's on-going operations. In light of the significance of the impact these products had on the sales growth of the Company, the sales results of these products have been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."

**Foreign Exchange** - Fluctuation in exchange rates impacts the comparative results and sales growth rates of the Company's underlying business. Management believes that excluding the impact of foreign exchange rate fluctuations from its sales growth provides investors a more meaningful comparison to historical financial results. The impact of foreign exchange rate fluctuations has been detailed in the "Unaudited Reconciliation of Sales by Product Line and Region."

**EDWARDS LIFESCIENCES CORPORATION**  
**Reconciliation of GAAP to Non-GAAP Financial Information**

Three Months Ended  
**March 31,**  
**2007      2006**

(in millions, except per share data)

---

**GAAP net income** \$33.2      \$45.9

Reconciling items:

**Special Charges (Gains)**

Realignment expenses	-	2.1
Gain on sale of products	-	(5.7)
Gain on patent settlement	-	(20.2)
Subtotal special gains	-	(23.8)

**Provision for income taxes**

Tax effect on non-GAAP adjustments (1)	-	9.4
--	---	-----

---

**Non-GAAP net income** **\$33.2      \$31.5**

---

**Non-GAAP earnings per share:**

Basic non-GAAP earnings per share	\$0.57	\$0.53
Diluted non-GAAP earnings per share (2)	\$0.54	\$0.50

**Weighted average shares outstanding:**

Basic	57.9	59.3
Diluted	63.5	64.6

(1) The tax effect on non-GAAP adjustments is calculated using the relevant tax jurisdiction of the transaction applying the local statutory tax rate.

(2) Diluted earnings per share is calculated by adding back \$1.0 million to net income for the quarter in interest expense related to the convertible debt, then dividing by the weighted average diluted shares outstanding.

**EDWARDS LIFESCIENCES CORPORATION**

**Unaudited Reconciliation of Sales by Product Line and Region  
(in millions)**

Sales by Product Line (Qtr)	1Q 2007	1Q 2006	Change	GAAP Growth Rate	2007 Adjusted		2006 Adjusted			Underlying % Growth*
					Discontinued Product Line Impact	1Q 2007 Underlying Sales	Discontinued Product Line Impact	FX Impact	1Q 2006 Underlying Sales	
Heart Valve Therapy	\$ 129.5	\$ 125.1	\$ 4.4	3.5%	\$ (1.7)	\$ 127.8	\$ (3.3)	\$ 2.9	\$ 124.7	2.5%
Critical Care	90.9	81.1	9.8	12.1%	-	90.9	-	1.9	83.0	9.5%
Cardiac Surgery Systems	16.8	23.3	(6.5)	(27.9%)	(3.1)	13.7	(10.1)	0.2	13.4	1.9%
Vascular	20.2	18.2	2.0	11.0%	-	20.2	(0.6)	0.7	18.3	10.6%
Other Distributed Products	6.7	9.0	(2.3)	(25.6%)	-	6.7	(0.6)	-	8.4	(16.7%)
<b>Total</b>	<b>\$ 264.1</b>	<b>\$ 256.7</b>	<b>\$ 7.4</b>	<b>2.9%</b>	<b>\$ (4.8)</b>	<b>\$ 259.3</b>	<b>\$ (14.6)</b>	<b>\$ 5.7</b>	<b>\$ 247.8</b>	<b>4.7%</b>

Sales by Region (Qtr)	1Q 2007	1Q 2006	Change	GAAP Growth Rate
United States	\$ 124.1	\$ 121.1	\$ 3.0	2.5%
Europe	73.9	64.7	9.2	14.2%
Japan	38.6	41.7	(3.1)	(7.4%)
Rest of World	27.5	29.2	(1.7)	(5.8%)
International	140.0	135.6	4.4	3.2%
<b>Total</b>	<b>\$ 264.1</b>	<b>\$ 256.7</b>	<b>\$ 7.4</b>	<b>2.9%</b>

\* Numbers may not calculate due to rounding.